<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491502</url>
  </required_header>
  <id_info>
    <org_study_id>HIFU/BG/TN/FS/2015</org_study_id>
    <nct_id>NCT02491502</nct_id>
  </id_info>
  <brief_title>Treatment of Benign Thyroid Nodules With FastScan HIFU</brief_title>
  <official_title>Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theraclion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theraclion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of the HIFU for the treatment of benign thyroid nodules&#xD;
      with the FastScan version using assessment of patient experience and adverse event reporting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Echopulse is specially designed, manufactured and CE marked for treating benign thyroid&#xD;
      nodules. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to&#xD;
      deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to&#xD;
      85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted&#xD;
      area.&#xD;
&#xD;
      In a previous european feasibility study performed at 1 site (Bulgaria), 20 benign thyroid&#xD;
      nodules were treated. The HIFU treatment was well tolerated and showed efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 day post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>3 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>7 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in volume of the thyroid nodule compared to Baseline at 6 months</measure>
    <time_frame>6 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day</measure>
    <time_frame>1 day post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days</measure>
    <time_frame>3 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days</measure>
    <time_frame>7 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction questionnaire</measure>
    <time_frame>6 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Absence of palpable lesion</measure>
    <time_frame>3 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Absence of palpable lesion</measure>
    <time_frame>6 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Cosmetic evaluation measured by questionnaire</measure>
    <time_frame>6 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator rated evaluation of the device</measure>
    <time_frame>Post treatment Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of gland vascularization at 3 months</measure>
    <time_frame>3 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of gland vascularization at 6 months</measure>
    <time_frame>6 months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Benign Thyroid Nodules</condition>
  <arm_group>
    <arm_group_label>Echopulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Echopulse HIFU</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Echopulse</intervention_name>
    <description>HIFU Under ultrasound guidance</description>
    <arm_group_label>Echopulse</arm_group_label>
    <other_name>Echopulse HIFU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient 18 years or older.&#xD;
&#xD;
          -  Patient presenting with at least one thyroid nodule with no signs of malignancy:&#xD;
&#xD;
               1. Non suspect clinically and at ultrasonography imaging&#xD;
&#xD;
               2. Benign cytological diagnosis at FNAB (fine-needle aspiration biopsy) from the&#xD;
                  last 6 months&#xD;
&#xD;
               3. Normal serum calcitonin&#xD;
&#xD;
               4. No history of neck irradiation&#xD;
&#xD;
          -  Normal TSH (thyroid-stimulating hormone)&#xD;
&#xD;
          -  Targeted nodule accessible and eligible to HIFU&#xD;
&#xD;
          -  Absence of abnormal vocal cord mobility at laryngoscopy&#xD;
&#xD;
          -  Nodule diameter ≥ 10mm measured by ultrasound&#xD;
&#xD;
          -  Composition of the targeted nodule(s) : predominantly solid&#xD;
&#xD;
          -  Patient has signed a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Head and/or neck disease that prevents hyperextension of neck&#xD;
&#xD;
          -  Known history of thyroid cancer or other neoplasias in the neck region&#xD;
&#xD;
          -  History of neck irradiation&#xD;
&#xD;
          -  Macrocalcification inducing a shadow in the thyroid significant enough to preclude the&#xD;
             HIFU treatment&#xD;
&#xD;
          -  Posterior position of the nodule if the thickness of the nodule is &lt;15mm&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Any contraindication to the assigned analgesia/anaesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roussanka Kovatcheva, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>roussanka_kov@yahoo.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Endocrinology USBALE</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

